Immunohistochemical expression of glucose transporter 1 in keratin-producing odontogenic cysts
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Vera-Sirera, B
- Forner-Navarro, L
Abstract
Background: Keratin-producing odontogenic cysts (KPOCs) are a group of cystic lesions that are often aggressive, with high rates of recurrence and multifocality. KPOCs included orthokeratinised odontogenic cyst (OOC) and parakeratotic odontogenic cysts, which are now considered true tumours denominated keratocystic odontogenic tumours (KCOTs). GLUT1 is a protein transporter that is involved in the active uptake of glucose across cell membranes and that is overexpressed in tumours in close correlation with the proliferation rate and positron emission tomography (PET) imaging results. Methods: A series of 58 keratin-producing odontogenic cysts was evaluated histologically and immunohistochemically in terms of GLUT1 expression. Different data were correlated using the beta regression model in relation to histological type and immunohistochemical expression of GLUT1, which was quantified using two different morphological methods. Results: KPOC cases comprised 12 OOCs and 46 KCOTs, the latter corresponding to 6 syndromic and 40 sporadic KCOTs. GLUT1 expression was very low in OOC cases compared with KCOT cases, with statistical significant differences when quantification was considered. Different GLUT1 localisation patterns were revealed by immunostaining, with the parabasal cells showing higher reactivity in KCOTs. However, among KCOTs cases, GLUT1 expression was unable to establish differences between syndromic and sporadic cases. Conclusions: GLUT1 expression differentiated between OOC and KCOT cases, with significantly higher expression in KCOTs, but did not differentiate between syndromic and sporadic KCOT cases. However, given the structural characteristics of KCOTs, we hypothesised that PET imaging methodology is probably not a useful diagnostic tool for KCOTs. Further studies of GLUT1 expression and PET examination in KCOT series are needed to confirm this last hypothesis.
Datos de la publicación
- ISSN/ISSNe:
- 1472-6831, 1472-6831
- Tipo:
- Article
- Páginas:
- 32-32
- Factor de Impacto:
- 0,746 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
BMC Oral Health BIOMED CENTRAL LTD
Citas Recibidas en Web of Science: 3
Documentos
- No hay documentos
Filiaciones
Keywords
- Glucose transporter protein; Immunohistochemistry; Keratin-producing odontogenic cyst; Keratocystic odontogenic tumour; Orthokeratinised odontogenic cyst; Positron emission tomography
Proyectos asociados
ENSAYO CLÍNICO FASE II, ABIERTO, DE ERLOTINIB Y BEVACIZUMAB EN PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO AVANZADO Y CON MUTACION DEL EGFR.
Investigador Principal: JOSÉ GÓMEZ CODINA
ETOP2-11/MO27911
ESTUDIO FASE II/III DE LY2157299 MONOHIDRATO EN MONOTERAPIA EN PACIENTES CON SÍNDROMES MIELODISPLÁSICOS DE RIESGO MUY BAJO, BAJO O INTERMEDIO.
Investigador Principal: GUILLERMO SANZ SANTILLANA
H9H-MC-JBAV . 2014
ESTUDIO FASE III ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO DE BKM120 EN COMBINACIÓN CON FULVESTRANT EN MUJERES POSTMENOPÁUSICAS CON CÁNCER DE MAMA LOCALMENTE AVANZADO O METASTÁSICO CON RECEPTORES HORMONALES POSITIVOS HER2 NEGATIVO QUE HAN PROGRESADO MIENTRAS O DESPUÉS DEL TRATAMIENTO CON UN INHIBIDOR DE LA AROMATASA.
Investigador Principal: ANA SANTABALLA BERTRÁN
CBKM120F2302 . 2012
ESTUDIO ALEATORIZADO Y CONTROLADO DE PLATINO-CETUXIMAB COMBINADOS CON DOCETAXEL (GRUPO TPEX) O CON 5FU (GRUPO EXTREME) EN PACIENTES CON CÁNCER EPIDERMOIDE DE CABEZA Y CUELLO RECURRENTE O METASTÁSICO.
Investigador Principal: MIGUEL PASTOR BORGOÑON
TPEXTREME . 2015
ENSAYO CLÍNICO FASE II ALEATORIZADO, ABIERTO Y MULTICÉNTRICO, PARA DETERMINAR LA TOXICIDAD Y EFICACIA DE QUIMIOTERAPIA PRE-QUIRÚRGICA CON O SIN BEVACIZUMAB EN PACIENTES CON CÁNCER DE OVARIO AVANZADO.
Investigador Principal: ANA SANTABALLA BERTRÁN
GEICO-1205 . 2014
ESTUDIO FASE II ALEATORIZADO DE TRATAMIENTO DE LOS PACIENTES JÓVENES DIAGNOSTICADOS DE LINFOMA B DIFUSO DE CÉLULA GRANDE CON IPI DE ALTO RIESGO CON R-CHOP VS BORTEZOMIB-R-CAP.
Investigador Principal: ISIDRO JARQUE RAMOS
BRCAP-GELTAMO12 . 2013
ESTUDIO DE FASE III, ALEATORIZADO, ABIERTO QUE COMPARA LA COMBINACIÓN DEL INHIBIDOR DE BRAF, (DABRAFENIB) Y EL INHIBIDOR DE MEK (TRAMETINIB), CON EL INHIBIDOR DE BRAF (VEMURAFENIB) EN PACIENTES CON MELANOMA CUTÁNEO NO RESECABLE (ESTADIO IIIC) O METASTÁSIC O (ESTADIO IV) CON LA MUTACIÓN BRAF V600E/K.
Investigador Principal: ROBERTO PEDRO DÍAZ BEVERIDGE
MEK116513
ENSAYO CLÍNICO FASE II PILOTO, ABIERTO, MULTICÉNTRICO Y PROSPECTIVO PARA EVALUAR LA SEGURIDAD Y EFICACIA DE PF299804, UN INHIBIDOR PAN-HER IRREVERSIBLE, EN PACIENTES CON GLIOBLASTOMA RECURRENTE CON AMPLIFICACIÓN DE EGFR O PRESENCIA DE LA MUTACIÓN EGFRVIII .
Investigador Principal: GASPAR REYNES MUNTANER
GEINO-11 . 2012
Cita
Vera B,Forner L,Vera F. Immunohistochemical expression of glucose transporter 1 in keratin-producing odontogenic cysts. BMC Oral Health. 2016. 16. p. 32-32. IF:1,481. (2).